Advanced Therapies

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: The latest advances in advanced therapies discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Register now to hear from the CGT experts

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Challenges and solutions in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Drug discovery #Multiomics

White Paper – Accelerating Pharma Innovation and Drug Discovery with 5D Multiomics

Today’s drug discovery teams face increasing pressure to accelerate timelines, improve translational success, and minimise costly clinical failures. Yet most platforms still rely on fragmented technologies that deliver partial or delayed insights—forcing you to reconstruct biology from disconnected data. AVITI24™ 5D multiomics platform offers a new path by capturing RNA,… Read More

#Whitepapers

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Experts explore developments in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Watch now: Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

#Advanced Therapies

Workflow – A complete workflow for full-length AAV sequencing

Ensuring the integrity of adeno-associated virus (AAV) vectors is critical for gene therapy success, yet traditional methods can miss key structural elements. Discover how nanopore sequencing enables comprehensive characterisation of AAV genomes — including inverted terminal repeats (ITRs), transgenes, and promoters — all in a single workflow. Read More

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has… Read More

#News #Regulatory

#Advanced Therapies #Biomanufacturing #Cell and gene therapy #Drug discovery #Manufacturing

New DDW Highlights podcast: 28 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent news that the FDA rejected Ultragenyx Pharmaceutical’s gene therapy due to manufacturing concerns,… Read More

#News

#Advanced Therapies #Biomanufacturing #Cell and gene therapy #Drug discovery #Manufacturing

This week in drug discovery (21-25 July) 

News round-up for 21-25 July by DDW Senior Digital Content Editor Diana Turner. Following the recent news that the FDA rejected Ultragenyx Pharmaceutical’s gene therapy due to manufacturing concerns, manufacturing has dominated the headlines this week, particularly significant investment in facilities in the US, and new guidelines… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

New DDW Highlights podcast: 21 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

This week in drug discovery (14-18 July) 

News round-up for 14-18 July by DDW Senior Digital Content Editor Diana Turner. This week’s news highlights reflect the incredible levels of innovation and investment, but also the hurdles to overcome, in developing gene therapies – breakthrough treatments in many genetic diseases that can bring their own unique… Read More

#News

#Advanced Therapies

DDW eReport: Cell therapy (beyond CAR-T) and opportunities for new medicines

With significant investment in development and manufacturing, the cell therapy market is expected to boom in the next five years. Download this In Focus eReport to gain a full understanding of the current market for cell therapies and the areas of greatest commercial potential for the future. The eReport includes:… Read More

Advanced therapies
#Advanced Therapies #Cell and gene therapy #Events #Opinion

Hot topics, news and discussions at Advanced Therapies Week 2025

Advanced Therapies Week (ATW) 2025 took place Dallas, US, from 20-23 January 2025. DDW’s Megan Thomas hears from industry experts in attendance and reports on news from the event.  Patient perspective Michalle Adkins, Director of Life Sciences Strategy and Direction at Emerson USA, said: “One of the most exciting things… Read More

#Business & Investment #Exclusive Content #Opinion